The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Tuccori, Marco, Franchini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918959/
https://www.ncbi.nlm.nih.gov/pubmed/33671893
http://dx.doi.org/10.3390/life11020144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918959/
https://www.ncbi.nlm.nih.gov/pubmed/33671893
http://dx.doi.org/10.3390/life11020144

Ejemplares similares